DMD #17590
4 Intentional and inadvertent exposures (i.e. environmental contamination, breast milk) of the developing neonate to xenobiotics raises significant concerns over the potential risks posed to the exposed neonate. However, ethical impediments and limited toxicity data in human paediatric populations hinders the assessment of such risk. Furthermore, evidence for age-dependent differences in susceptibility to toxicity precludes a simple adult-to-neonate extrapolation of toxicity risk based upon toxicology studies in adult populations (Clark et al., 2004; Ginsberg et al., 2004b) . A need exists, then, for predictive paradigms for risk assessment in human paediatric populations.
Pharmacokinetic processes, particularly elimination mechanisms, often underlie these agerelated differences in susceptibility to toxicity. Most elimination processes undergo significant ontogeny (Alcorn and McNamara, 2002a) and their maturation status in the developing neonate may determine toxicological outcomes following a xenobiotic exposure (Ginsberg et al., 2004a; Barton, 2005) . Consequently, knowledge of a neonate's elimination capacity is critical for toxicological risk assessments. To address this issue, recent efforts to use available data on the ontogeny of xenobiotic elimination mechanisms in humans and animals have lead to models that allow predictions of xenobiotic elimination in the developing neonate (Alcorn and McNamara, 2002b; Brent, 2004; Barton, 2005; Jarabek et al., 2005; Bjorkman, 2006; Edginton et al., 2006 ; DMD #17590 5 substrate) exposures in children and represents a feasible approach for risk assessment purposes.
Predictions of xenobiotic elimination capacity alone, though, offer little understanding on mechanisms of toxicity and mitigating genetic and environmental factors contributing to interindividual variation in toxicity. To facilitate our understanding of age-dependent differences in susceptibility to toxicity an appropriate developmental animal model system remains mandatory (Graeter and Mortensen, 1996; Koren et al., 2003; Brent, 2004) .
Our labs previously developed an ontogeny model of hepatic CYP-mediated elimination based on an in vitro-in vivo extrapolation of published CYP activity data from age-specific human fetal and infant hepatic microsomes. Our review outlines the theoretical framework for the model (Alcorn and McNamara, 2002b) . Briefly, the model involves scaling in vitro hepatic intrinsic clearance data to in vivo intrinsic clearance and the extrapolation of known adult intrinsic clearance values to any age during postnatal development. This extrapolation occurs via a scaling factor (the Infant Scaling Factor), which incorporates age-dependent changes in hepatic scaling factors and CYP activity. Critical assumptions of the model include: 1) microsomal protein content is constant and independent of developmental age; 2) K M values are constant and not a function of developmental age; 3) V Max is proportional to functional enzyme level and activity from one substrate will accurately predict activity for all substrates of that enzyme; 4) uptake and efflux transporters do not contribute significantly to intrinsic clearance; 5) the drug is a low extraction ratio drug; and 6) the elimination pathways in the adult are known and the infant shares the same pathways.
Since, interspecies extrapolation of developmental toxicity data remains a practical option to elucidate the impact of development on susceptibility to toxicity, we propose a similar model approach for rat hepatic CYP ontogeny as a means of providing a predictive paradigm for risk This article has not been copyedited and formatted. The final version may differ from this version. DMD Fast Forward. Published on September 19, 2007 as DOI: 10.1124 at ASPET Journals on July 7, 2017 dmd.aspetjournals.org Downloaded from assessment. Comparative analyses of human and rat CYP enzyme maturation (Cresteil, 1987; Rich and Boobis, 1997) and CYP enzyme substrate specificity and regulation highlight important species differences between the rat and human. Furthermore, differences in the rates and patterns of CYP maturation (Alcorn and McNamara, 2002a ) may result in species differences in the parameterization of the model. Nevertheless, CYP enzyme mechanisms are similar across species, which suggests model assumptions remain the same regardless of species. However, before any toxicokinetic model of CYP ontogeny in rat can be developed and used to provide robust predictions of hepatic CYP-mediated elimination, we must first evaluate the appropriateness of the model's underlying assumptions.
The purpose of this study is to conduct investigations into the key assumptions of the model of hepatic CYP ontogeny. We use two developmentally dissimilar CYP enzymes, CYP2E1 and CYP1A2 and male Sprague-Dawley rats at various fetal, neonatal, juvenile, and adult age groups to provide critical information on the model's assumptions. The implications of the findings on the validity of the model are discussed.
livers rapidly excised and rinsed in cold 0.9% NaCl, weighed and flash frozen in liquid nitrogen, and stored at -80°C until microsomal preparation. All procedures were conducted in accordance with the Canadian Council of Animal Care guidelines for the care and use of laboratory animals and were approved by the Animal Care and Supply Committee of the University of Saskatchewan.
Preparation of Hepatic Microsomes. Hepatic microsomes were prepared as previously described (Elbarbry et al., 2007) . Protein concentrations of microsomal preparations were determined in triplicate by the method of Lowry et al. (Lowry et al., 1951) using bovine serum albumin as a calibration standard.
Microsomal Incubations with CYP2E1 and CYP1A2 Probe Substrates. Preliminary experiments in 50-day old male rat hepatic microsomes were conducted to determine the optimum incubation conditions (incubation time and microsomal protein content) to give linear metabolite formation kinetics for CYP2E1-mediated hydroxylation of chlorzoxazone (CZX) and ρ-nitrophenol (PNP) and CYP1A2-mediated phenacetin O-dealkylation (POD) and methoxyresorufin O-dealkylation (MROD) activities. Michaelis-Menten parameters, K M and V Max , for CYP2E1 and CYP1A2 were determined by measuring metabolite formation velocities of CZX and MROD at substrate concentrations of 0 to 1000 µM and 0 to 1000 nM, respectively.
With PNP and phenacetin, metabolite formation velocities were measured at saturating probe substrate concentrations (500 µM and 150 µM, respectively) in age-specific rat hepatic microsomes to provide estimates of V max .
HPLC Analysis. For CYP2E1, 6-hydroxylation of chlorzoxazone in rat hepatic microsomal preparations was quantified using an HPLC analysis as described (Elbarbry et al., 2007) . For the second probe substrate, PNP hydroxylation (CYP2E1 probe) was assayed as reported previously DMD #17590 (Elbarbry et al., 2006) . Calibration curves were constructed from known concentrations of 6-OH CZX and 50 µL of the internal standard (0.078 mM umbelliferone) or known concentrations of 4-nitrocatechol and 50 µL of internal standard (salicylamide, (6 µg/mL) added to heatinactivated (55°C for 5 min) rat hepatic microsomes. The calibration standards were diluted with 50 mM phosphate buffer (pH 7.4) to achieve calibration standards of 0.31-40 µM for 6-OH CZX or 0.1-40 µM for 4NC in a total volume of 0.5 mL. Three quality control (QC) samples at 0.625 µM (low), 1.25 µM (medium), and 5 µM (high) for 6-OH CZX or 0.5 µM (low), 5 µM (medium), and 20 µM (high) for 4NC were prepared independent of those used for the calibration curves. Coefficients of determination were greater than 0.999 for all calibration curves. Intra-day and inter-day precisions were less than 14%. The accuracy of estimated metabolite concentrations ranged from 91-113%.
For CYP1A2, Phenacetin-O-dealkylation (CYP1A2 probe) was assayed by a published HPLC method (von Moltke et al., 1996) using caffeine as an internal standard. UV absorbance was monitored at 254 nm (λ max for acetaminophen). The mobile phase consisted of 50 mM potassium dihydrogen phosphate and acetonitrile at a ratio of 85:15 (v/v (%) ) and delivered at 1.0 mL/min. Calibration curves were constructed from known concentrations of resorufin or acetaminophen and the internal standard (caffeine 5 µg/mL) added to heat-inactivated (55°C for 5 min) rat hepatic microsomes and diluted with 50 mM phosphate buffer (pH 7.4) to achieve calibration standards of 0.04-2 nM for resorufin and 0.2-20 µM for acetaminophen in a total volume of 0.5 mL. Three quality control (QC) samples at 0.1 nM (low), 0.4 nM (medium), and 2 nM (high) for resorufin and 0.5 µM (low), 2 µM (medium), and 10 µM (high) for acetaminophen were prepared independent of those used for the calibration curves. Coefficients of determination were greater than 0.999 for all calibration curves. Intra-and interday precision was <14% and <9% for resorufin and acetaminophen, respectively, and accuracy was within 15% of the nominal value for both HPLC assays. Scaling Factors. Hepatic scaling factors for a particular age (HSF (t) ) were estimated from the product of microsomal protein yield (MP (t) ) (mg microsomal protein per gram liver) and liver weight (g) (LW (t) ) normalized to body weight (g) (BW (t) ) as a function of developmental age, t, according to Equation 1.
CYP1A2 and CYP2E1 Protein
Infant scaling factors at a particular age, t (ISF (t) ) were estimated from the product of HSF (t) and
V Max values at the same age, t (V Max,(t) ) normalized to the product of the respective adult values according to Equation 2.
Data Analysis. All data within the same age was reported as mean±SD. 
Results

Hepatic scaling factor (HSF) as a function of developmental age.
To evaluate whether microsomal protein content remains constant with developmental age (the first major assumption of the ontogeny model of CYP enzyme activity) we measured total body and liver weights and liver microsomal protein content (mg per g liver) in fetal (gestation day 20), neonatal, juvenile, and adult age groups ( Table 1) . As expected, mean total body and liver weights increased with postnatal age, with the most prominent increases occurring during puberty (PD42-PD63). The age-dependent increase in liver and body weights was associated with marked interindividual variation, which reflects the normal variation in rates and patterns of body and organ growths typically observed in animal species. The average microsomal protein content per gram of liver (MP) was significantly lower than adult levels in fetal and early postnatal age groups. After PD5, MP levels were similar to adult values.
Closer examination of the data showed mean liver weight normalized to total body weight For CYP1A2, the apparent K M estimates for MROD for PD5 and PD7 were significantly higher than adult values (>2.5-fold adult values) (Figure 2) . No significant differences in apparent K M estimates were observed for PD age groups ≥ 10 days. The data did not allow estimation of K M values in fetal, PD1, and PD3 age groups, although activity was detected at low levels at PD3.
V Max as a function of development.
To assess whether enzyme activity (V Max ) is proportional to enzyme level during ontogeny (the third major assumption of the ontogeny model of CYP enzyme activity) we measured CYP1A2 and CYP2E1activity at saturating probe substrate concentrations in rat hepatic microsomes at different developmental stages and compared this activity to immunoquantifiable CYP levels at the same developmental age. MROD activity ( Figure 3A ) was first detected at PD3, but below the level of quantification of the HPLC assay.
PD5 and PD7 hepatic microsomes demonstrated significantly lower MROD activity at 11% and 20% adult activity, respectively. MROD activity increased significantly to reach ~1.75-fold the adult values by PD28. However, after weaning (PD28) and during puberty (PD42-63) V Max values fell to adult values. Although, the marked increase in MROD activity between PD14 and PD21 corresponded to a marked increase in age-dependent hepatic scaling factors (Figure 1 ), activity declined after PD28 to the adult value by PD42, unlike the hepatic scaling factor.
We did not detect CZX hydroxylase activity ( Figure 3B To determine whether enzyme activity (V Max ) from one substrate will accurately predict the level of activity for all substrates of the enzyme we correlated the V Max values at each age group from one CYP probe substrate with the second probe substrate ( Figure 5 ). Figure 5 suggests a strong and significant correlation between the activity of one specific substrate relative to a second specific substrate for both CYP1A2 (r = 0.68, P<0.05; data not shown due to low variability in the POD data relative to the MROD data) and CYP2E1 (r = 0.69, P<0.05). Figure 6 shows the postnatal developmental pattern of CYP1A2 and CYP2E1 when scaled to the whole body. For both CYP enzymes whole body CYP activity is low at birth and rapidly increases to maximum levels at the end of weaning (PD28). Thereafter, whole body CYP activity 
Discussion
The very limited toxicological data in human paediatric populations prompted efforts to advance physiologically based pharmacokinetic models in animal developmental toxicology systems for human paediatric risk assessments (Brent, 2004; Clark et al., 2004) . By relating xenobiotic elimination capacity to the time course of CYP maturation, the previously reported ontogeny model of CYP activity (Alcorn and McNamara, 2002b ) contributes to such efforts. A valid and robust model can facilitate study design and dosage selection for developmental toxicology studies and identify when age-dependent differences in xenobiotic elimination account for differences in susceptibility to toxicity. To this end, we evaluated the underlying assumptions of the CYP ontogeny model (Alcorn and McNamara, 2002b ) in a toxicologically relevant animal system. The assessments in the rat identified important departures from model assumptions and we discuss their possible underlying causes and overall significance below.
Hepatic Scaling Factor
In vitro-in vivo extrapolation of intrinsic clearance data requires knowledge of developmental changes in microsomal protein content, liver weight, and body weight (Carlile et al., 1997; Houston and Carlile, 1997; Obach et al., 1997) . In the human CYP ontogeny model, we obtained information on the age-dependent changes in liver and body weight from the literature, but assumed hepatic microsomal protein content on a per gram liver basis remained constant throughout postnatal development and used a published literature value (Alcorn and McNamara, 2002b) . Any age-related changes in hepatic scaling factors, then, became dependent solely on developmental changes in liver weight normalized to body weight.
In this study rat hepatic microsomal protein content per gram liver increased significantly during the neonatal period, reached a maximum at puberty and declined to adult levels in the This article has not been copyedited and formatted. The final version may differ from this version. early post-pubertal stage. The data is consistent with rat hepatic microsomal content described in a limited number of postnatal, prepubertal and pubertal age groups and adults in the literature (Borlakoglu et al., 1993; Kishi et al., 2005) . Postnatal changes in microsomal protein content in the rat suggests a need for similar investigations with human paediatric livers (Johnsrud et al., 2003; Johnson et al., 2006) . Interestingly, the age-dependent changes in rat hepatic scaling factors became a function of changes in microsomal protein content rather than liver weight to body weight ratio, which stayed relatively constant and independent of developmental stage.
Although these findings contradict a model assumption, this contradiction does not necessarily weaken its potential value. These results merely suggest the need to measure hepatic microsomal protein content in paediatric livers to incorporate its developmental change into the modeling process to provide predictive estimates of the infant scaling factors.
Clearance as a Function of Hepatic Metabolic Enzyme Activity
The ontogeny model makes the limiting assumption that systemic clearance is a function of hepatic metabolic enzyme activity (i.e. the xenobiotic is a low hepatic extraction ratio compound) and uptake and efflux transporters make no contribution to intrinsic clearance. We used probes (Kobayashi et al., 2002) that are known low hepatic extraction ratio compounds, but these probes have not been assessed as transporter substrates. Intrinsic clearance estimates are affected by substrates where membrane transporters act as a rate limiting process of metabolic clearance (Ito et al., 1998) . At present the model makes no accommodation for such substrates but has the potential to incorporate transport processes in the infant scaling factor determinations. Nevertheless, the model can be applied to many xenobiotics as most are low extraction ratio compounds and passive diffusion governs their distribution into the liver. 
Intrinsic Clearance
The experimental data failed to support two critical assumptions of the ontogeny model (i.e. age-dependent changes in intrinsic clearance reflect changes only in V Max and K M remains constant throughout development) (Alcorn and McNamara, 2002b) . The data suggests a need to incorporate developmental changes in K M estimates in the model building process (i.e. model the V max /K M ratio) instead of modeling only changes in V Max . The incorporation of a new parameter, which undergoes interindividual variability during development, will increase the model's complexity and possibly result in greater uncertainty in its parameter estimates. However, study design limitations may explain this apparent divergence from model assumptions. Specifically, we question probe substrate specificity in paediatric hepatic microsomal preparations. At best probes are selective (not specific) for the CYP of interest (Kobayashi et al., 2002; Lu et al., 2003) and selectivity is dependent upon substrate concentration (Kato and Yamazoe, 1994) .
Since different CYP enzymes undergo variable rates and patterns of development (Borlakoglu et al., 1993; Rich and Boobis, 1997; Alcorn and McNamara, 2002a) , CYP enzymes that contribute a small percentage to probe metabolism in adult stages may play a larger role during specific paediatric stages. In the study, differences in K M values may reflect the contribution of other CYP enzymes and the estimated K M values will then reflect a hybrid of contributing enzymes.
Eadie-Hofstee plots (data not shown), though, gave no evidence of systematic deviation from a single site Michaelis-Menten model at higher substrate concentrations for CZX, but curvilinear plots were observed for MROD suggesting the contribution of at least a second low affinity enzyme site. Furthermore, nonspecific binding to microsomal protein (Obach, 1997; Obach et al., 1997) and differences in the membrane environment of the endoplasmic reticulum (Dallner et al., 1966) can influence apparent K M estimates. We cannot ignore the potential for age-dependent The data on the age-dependent changes in CYP2E1 and CYP1A2 activity are consistent with the few reports of rat CYP ontogeny (Jahn et al., 1993; Wu and Cederbaum, 1993; Rich and Boobis, 1997; Iba et al., 2000; Anand et al., 2006) . However, the observed lack of correlation between developmental increases in CYP activity and immunoreactive protein levels violates an important model assumption. Posttranslational modifications with development that markedly influence enzyme activity may explain the apparent discordancy. Alternatively, other CYP enzymes whose development precedes CYP2E1 and CYP1A2 maturation may contribute significantly to probe metabolism at particular postnatal age stages. Finally, inadequate antibody specificity (i.e. cross-reactivity with other CYP enzymes) may also contribute to this lack of congruence. For these reasons, then, CYP immunoreactive protein levels may not necessarily reflect enzyme activity (Johnsrud et al., 2003) . Interestingly, immunohistochemical analysis revealed homogeneous expression of CYP1A2 and CYP2E1 in the hepatic acinus in fetal and early postnatal livers with increasing preferential localization of CYP1A2 and CYP2E1 expression in perivenous hepatocytes with postnatal development (Elbarbry et al., 2007) . With intrasinusoidal gradients in oxygen tension and substrate supply, age-dependent changes in intrahepatic CYP expression patterns will likely have some influence on CYP regulation and This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. 
